Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986.
Explore this paper's citation graph
Summary
There were no significant differences in efficacy between the two treatment groups, and the incidence of severe acute toxicities was higher for those receiving M-CAVI.
- Type
- article
- Published
- 2012-01-10
- Cited by
- 714
- References
- 43
- Access
- Open access
- OpenAlex
- https://openalex.org/W2148562299
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:41314090
Keywords
Carboplatin, Medicine, Gemcitabine, Mucositis, Internal medicine
References
- General guidelines for the management of older patients with cancer.
- Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer.
- Prediction of creatinine clearance from serum creatinine.
- Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium
- Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy.
- Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer.
- Carboplatin‐based versus cisplatin‐based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma
- Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin‐based chemotherapy
- Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial.
- Randomised phase II trial of carboplatin and iproplatin in advanced urothelial cancer.
- Combination of gemcitabine and oxaliplatin in urothelial cancer patients with severe renal or cardiac comorbidities
- Single-Agent Gemcitabine in Previously Untreated Elderly Patients with Advanced Bladder Carcinoma: Response to Treatment and Correlation with the Comprehensive Geriatric
- Comparison between a cisplatin‐containing regimen and a carboplatin‐containing regimen for recurrent or metastatic bladder cancer patients: A randomized phase II study
- Physicians' judgement and comprehensive geriatric assessment (CGA) select different patients as fit for chemotherapy.
- A carboplatin‐based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium
- International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency.
- Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.
- Gemcitabine Monotherapy as Second-Line Treatment in Cisplatin-Refractory Transitional Cell Carcinoma – Prognostic Factors for Response and Improvement of Quality of Life
- Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma
- New developments in first- and second-line chemotherapy for transitional cell, squamous cell and adenocarcinoma of the bladder
Cited by
- Neoadjuvant Chemotherapy for Invasive Bladder Cancer
- Medikamentöse Therapie des fortgeschrittenen Blasenkarzinoms
- Controversies in the treatment of invasive urothelial carcinoma: a case report and review of the literature
- Atezolizumab in invasive and metastatic urothelial carcinoma
- Gemcitabine plus split-dose cisplatin could be a promising alternative to gemcitabine plus carboplatin for cisplatin-unfit patients with advanced urothelial carcinoma
- Sequential chemotherapy using gemcitabine + carboplatin followed by gemcitabine + carboplatin + docetaxel for advanced upper-tract urothelial cancer
- ESMO Handbook of Cancer in the Senior Patient
- Low‐dose maintenance gemcitabine‐carboplatin chemotherapy could be an alternative to continuous standard chemotherapy for patients with metastatic urothelial carcinoma
- Tools to improve clinical trial design in urothelial cancer
- Bladder cancer in the elderly patient: challenges and solutions
- Erstlinienchemotherapie beim Harnblasenkarzinom
- Optimizing systemic therapy for bladder cancer.
- Targeting the VEGF pathway in metastatic bladder cancer
- Reliability of estimated glomerular filtration rate in patients treated with platinum containing therapy
- Bayesian designs and the control of frequentist characteristics: A practical solution
- First-line treatment of metastatic disease: cisplatin-ineligible patients.
- Docetaxel for the treatment of bladder cancer
- Novel Molecular Targets for the Therapy of Urothelial Cancer.
- Update in Systemic Therapy of Urologic Malignancies
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Related papers
- Acute Oral Mucositis During Hypo-Fractionated Radiation in Squamous Cell Carcinoma of Oral Cavity.
- [Management of oral mucositis in patients with head and neck cancer receiving chemoradiotherapy and/or molecular targeted therapy].
- The role of gemcitabine in first-line treatment of advanced ovarian carcinoma.
- A phase I study of gemcitabine and carboplatin in non-small cell lung cancer.
- Carboplatin and gemcitabine in stage IV non small cell lung cancer: beyond cisplatin in palliative chemotherapy.
- Fixed-dose rate gemcitabine plus carboplatin in relapsed, platinum-sensitive ovarian cancer patients: results of a three-arm Phase I study.
- Gemcitabine and carboplatin in combination: an update of phase I and phase II studies in non-small cell lung cancer.
- Gemcitabine in combination with new platinum compounds: an update.
- Analysis of the Cytotoxic Activity of the Carboplatin and Gemcitabine Combination
- Nab-paclitaxel plus gemcitabine as first-line palliative chemotherapy in a patient with metastatic pancreatic cancer with Eastern Cooperative Oncology Group performance status of 2.